Shop

SPIRONOLACTONE 50MG TAB (TEVA)
₵3.55
Add to wishlist Add to compareAsk about productDescription
Spironolactone 50 mg Tablets (Teva) contain spironolactone, a potassium-sparing diuretic and aldosterone antagonist.
Primary Medical Uses:
– Treatment of edema caused by heart failure, liver cirrhosis, or kidney disease.
– Management of hypertension (high blood pressure).
– Treatment of primary hyperaldosteronism (excess aldosterone production).
– Used off-label for conditions such as acne, hirsutism, and certain hormone-related disorders.
Drug Class:
– Potassium-sparing diuretic and mineralocorticoid receptor antagonist.
General Mechanism of Action:
– Spironolactone blocks aldosterone, a hormone that promotes sodium and water retention.
– This inhibition leads to increased excretion of sodium and water while conserving potassium, helping reduce fluid buildup and lower blood pressure.
Common Forms:
– Oral tablets, commonly available in 25 mg, 50 mg, and 100 mg strengths.
Dosage Instructions:
– Dosage varies depending on the condition.
– Typically, 50 mg daily is a common starting dose for conditions like edema or hypertension.
– Tablets are generally taken once or twice daily with or after food.
– Follow healthcare provider’s instructions for dosing adjustments.
Side Effects, Contraindications, or Interactions:
– Common side effects: dizziness, headache, gastrointestinal upset, breast tenderness or enlargement, and elevated potassium levels.
– Serious risks: hyperkalemia (high potassium), kidney dysfunction, severe allergic reactions.
– Contraindications: hyperkalemia, severe renal impairment, Addison’s disease, or allergy to spironolactone.
– Caution if used with other potassium-increasing drugs (e.g., potassium supplements, ACE inhibitors).
– Regular monitoring of blood potassium and kidney function is recommended during treatment.
Spironolactone 50 mg tablets from Teva are used to manage fluid retention, hypertension, and specific hormone-related conditions under medical supervision.




Reviews
There are no reviews yet.